Therefore, our study objective was to evaluate the association between the use of GLP-1 receptor agonists (GLP-1 RAs), considered as a single class, and the risk of pancreatitis in a comorbidity-free subgroup of patients with type 2 diabetes mellitus (T2DM) in the United States, using propensity score matching (PSM) to balance baseline characteristics. The gene discussed is GLP1R; the disease is pancreatitis.